|
6 Companies |
|
2 Products |
|
2 Products |
|
1 Mechanism of Action |
|
0 Trials |
|
52 News |
|
| 12» |
- | Ixiaro (IC51) / Valneva
Trial completion, Enrollment change: Cellular and Humoral Immunity in Elderly After Immunization With a Japanese Encephalitis Vaccine (clinicaltrials.gov) - Mar 30, 2018
P4, N=60, Completed, Sponsor: Medical University of Vienna
Enrolling by invitation --> Completed | N=30 --> 60
- |||| Encevac (freeze-dried, vero cell culture-derived, inactivated Japanese encephalitis vaccine) / Meiji Seika
Trial completion, Enrollment change: BR-JELITE: Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis Vaccineinj (clinicaltrials.gov) - Feb 6, 2017
P4, N=94, Completed, Sponsor: Boryung Pharmaceutical Co., Ltd
Enrolling by invitation --> Completed | N=30 --> 60 Recruiting --> Completed | N=188 --> 94
- | Trial completion, Trial primary completion date: A Clinical Trial for Inactivated Japanese Encephalitis Vaccine in Healthy Chinese Infants (clinicaltrials.gov) - Sep 1, 2016
P3, N=900, Completed, Sponsor: Jiangsu Province Centers for Disease Control and Prevention
Recruiting --> Completed | N=188 --> 94 Active, not recruiting --> Completed | Trial primary completion date: Feb 2016 --> Jun 2016
- Trial completion, Trial primary completion date: MR+JE: Immunogenicity of Co-administration of Measles and Japanese Encephalitis Vaccines (clinicaltrials.gov) - Aug 1, 2016
P4, N=1043, Completed, Sponsor: Centers for Disease Control and Prevention, China
Active, not recruiting --> Completed | Trial primary completion date: Feb 2016 --> Jun 2016 Recruiting --> Completed | Trial primary completion date: Mar 2016 --> Jun 2016
- | New P2 trial: Safety and Immunogenicity of JECEVAX in Young Children (clinicaltrials.gov) - Jun 28, 2016
P2, N=200, Completed, Sponsor: National Institute of Hygiene and Epidemiology, Vietnam
- Stamaril (yellow fever vaccine) / Sanofi, Ixiaro (IC51) / Valneva
Trial completion: The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans (clinicaltrials.gov) - Apr 20, 2016
P2, N=84, Completed, Sponsor: Singapore General Hospital
Recruiting --> Completed | Trial primary completion date: Mar 2016 --> Jun 2016 Active, not recruiting --> Completed
- | New P4 trial: MR+JE: Immunogenicity of Co-administration of Measles and Japanese Encephalitis Vaccines (clinicaltrials.gov) - Dec 31, 2015
P4, N=1056, Recruiting, Sponsor: Centers for Disease Control and Prevention, China
- Imojev (live attenuated Japanese encephalitis chimeric virus vaccine) / Sanofi
New trial: Immunogenicity of a JE-CV as a Booster Dose After a Primary Vaccination With SA14-14-2 Vaccine (clinicaltrials.gov) - Nov 14, 2015
P=N/A, N=50, Completed, Sponsor: Chulalongkorn University
- | Enrollment closed: A Clinical Trial for Inactivated Japanese Encephalitis Vaccine in Healthy Chinese Infants (clinicaltrials.gov) - Sep 2, 2015
P3, N=900, Active, not recruiting, Sponsor: Jiangsu Province Centers for Disease Control and Prevention
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| Encevac (freeze-dried, vero cell culture-derived, inactivated Japanese encephalitis vaccine) / Meiji Seika
New P4 trial: BR-JELITE: Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis Vaccineinj (clinicaltrials.gov) - Aug 26, 2015
P4, N=188, Recruiting, Sponsor: Boryung Pharmaceutical Co., Ltd
- ||| Imojev (live attenuated Japanese encephalitis chimeric virus vaccine) / Sanofi
Enrollment closed, Trial primary completion date: Post-licensure Safety Study of IMOJEV (clinicaltrials.gov) - Aug 19, 2015
P4, N=10000, Active, not recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Apr 2015
- | Imojev (live attenuated Japanese encephalitis chimeric virus vaccine) / Sanofi
New P4 trial: Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX (clinicaltrials.gov) - Aug 18, 2015
P4, N=50, Completed, Sponsor: Siriraj Hospital
- ||| Ixiaro (IC51) / Valneva
Trial completion, Trial primary completion date, Adverse events: Safety Surveillance After Immunization With IXIARO (clinicaltrials.gov) - Mar 10, 2015
P=N/A, N=20000, Completed, Sponsor: Valneva Austria GmbH
Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Apr 2015 Active, not recruiting --> Completed | Trial primary completion date: Jun 2014 --> Jun 2013
- ||||||| Imojev (live attenuated Japanese encephalitis chimeric virus vaccine) / Sanofi
Trial completion: Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Toddlers (clinicaltrials.gov) - Mar 3, 2015
P3, N=591, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Active, not recruiting --> Completed | Trial primary completion date: Jun 2014 --> Jun 2013 Enrolling by invitation --> Completed
- || New P3 trial: A Clinical Trial for Inactivated Japanese Encephalitis Vaccine in Healthy Chinese Infants (clinicaltrials.gov) - Feb 20, 2015
P3, N=900, Recruiting, Sponsor: Jiangsu Province Centers for Disease Control and Prevention
- Trial completion, Trial primary completion date: 6-year Antibody Check After Third Vaccination Against Japanese Encephalitis (clinicaltrials.gov) - Feb 20, 2015
P4, N=67, Completed, Sponsor: Medical University of Vienna
Enrolling by invitation --> Completed Not yet recruiting --> Completed | Trial primary completion date: Dec 2014 --> Jun 2014
- ||||||| Ixiaro (IC51) / Valneva
Trial completion, Trial primary completion date: Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country (clinicaltrials.gov) - Dec 19, 2014
P3, N=300, Completed, Sponsor: Valneva Austria GmbH
Not yet recruiting --> Completed | Trial primary completion date: Dec 2014 --> Jun 2014 Active, not recruiting --> Completed | Trial primary completion date: Oct 2013 --> Nov 2011
- Stamaril (yellow fever vaccine) / Sanofi, Ixiaro (IC51) / Valneva
Enrollment closed: The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans (clinicaltrials.gov) - Dec 6, 2014
P2, N=100, Active, not recruiting, Sponsor: Singapore General Hospital
Active, not recruiting --> Completed | Trial primary completion date: Oct 2013 --> Nov 2011 Recruiting --> Active, not recruiting
- ||||||| Trial completion: Immunogenicity and Safety of Inactivated Vero Cell Derived Japanese Encephalitis Vaccine in Thai Children (clinicaltrials.gov) - Nov 18, 2014
P3, N=152, Completed, Sponsor: Mahidol University
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| Trial primary completion date: Study of ChimeriVax (clinicaltrials.gov) - Aug 15, 2014
P3, N=1200, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Active, not recruiting --> Completed Trial primary completion date: Sep 2009 --> May 2009
- Trial primary completion date: A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2 (clinicaltrials.gov) - Jun 12, 2014
P4, N=17, Completed, Sponsor: Indian Institute of Science
Trial primary completion date: Sep 2009 --> May 2009 Trial primary completion date: May 2013 --> Oct 2013
- Trial completion: A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2 (clinicaltrials.gov) - Jun 12, 2014
P4, N=17, Completed, Sponsor: Indian Institute of Science
Trial primary completion date: May 2013 --> Oct 2013 Recruiting --> Completed
- |||| Trial completion: Immunogenicity and Safety of ChimeriVax (clinicaltrials.gov) - Mar 4, 2014
P2, N=300, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Encevac (freeze-dried, vero cell culture-derived, inactivated Japanese encephalitis vaccine) / Meiji Seika
Trial completion: Clinical Trial to Assess the Immunogenicity and Safety of the Vero Cell-derived JE Vaccine in Korea (clinicaltrials.gov) - Jan 28, 2014
P3, N=205, Completed, Sponsor: Boryung Pharmaceutical Co., Ltd
Active, not recruiting --> Completed Recruiting --> Completed
- | New P4 trial: 6-year Antibody Check After Third Vaccination Against Japanese Encephalitis (clinicaltrials.gov) - Jan 15, 2014
P4, N=60, Not yet recruiting, Sponsor: Medical University of Vienna
- || Ixiaro (IC51) / Valneva
Enrollment closed, Adverse events: Safety Surveillance After Immunization With IXIARO (clinicaltrials.gov) - Nov 24, 2013
P=N/A, N=20000, Active, not recruiting, Sponsor: Valneva Austria GmbH
Recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| Imojev (live attenuated Japanese encephalitis chimeric virus vaccine) / Sanofi
New P4 trial: Post-licensure Safety Study of IMOJEV (clinicaltrials.gov) - Nov 11, 2013
P4, N=10000, Recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
- ||||||| Trial completion: Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects (clinicaltrials.gov) - Nov 3, 2013
P3, N=660, Completed, Sponsor: Novartis Vaccines
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Enrollment change: Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine (clinicaltrials.gov) - Oct 13, 2013
P4, N=497, Completed, Sponsor: Changchun Keygen Biological Products Co., Ltd.
Active, not recruiting --> Completed N=368 --> 497
- Stamaril (yellow fever vaccine) / Sanofi, Ixiaro (IC51) / Valneva
Enrollment open: The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans (clinicaltrials.gov) - Oct 5, 2013
P2, N=100, Recruiting, Sponsor: Singapore General Hospital
N=368 --> 497 Not yet recruiting --> Recruiting
- | Stamaril (yellow fever vaccine) / Sanofi, Ixiaro (IC51) / Valneva
New P2 trial: The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans (clinicaltrials.gov) - Sep 12, 2013
P2, N=100, Recruiting, Sponsor: Singapore General Hospital
- Trial completion: Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine (clinicaltrials.gov) - Sep 5, 2013
P4, N=497, Completed, Sponsor: Changchun Keygen Biological Products Co., Ltd.
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||||||| Imojev (live attenuated Japanese encephalitis chimeric virus vaccine) / Sanofi
Trial completion: Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV (clinicaltrials.gov) - Aug 15, 2013
P3, N=274, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Recruiting --> Completed Active, not recruiting --> Completed
- Trial completion, Head-to-Head: Lot-to-lot Consistency Trial of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine (clinicaltrials.gov) - Aug 1, 2013
P4, N=0, Completed, Sponsor: Program for Appropriate Technology in Health
Active, not recruiting --> Completed Recruiting --> Completed
- ImmunoRel (immunoglobulin G) / Reliance Life Sci
New P2 trial: Safety and Efficacy Study of Intravenous Immunoglobulin to Treat Japanese Encephalitis (clinicaltrials.gov) - May 15, 2013
P2, N=22, Completed, Sponsor: University of Liverpool
- ||||||| Imojev (live attenuated Japanese encephalitis chimeric virus vaccine) / Sanofi
Trial completion: Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers (clinicaltrials.gov) - Mar 27, 2013
P3, N=542, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Recruiting --> Completed Active, not recruiting --> Completed
- | New P4 trial: Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine (clinicaltrials.gov) - Mar 18, 2013
P4, N=497, Completed, Sponsor: Changchun Keygen Biological Products Co., Ltd.
- Ixiaro (IC51) / Valneva
Trial withdrawal: Immune Response in IXIARO Batch JEV09L37 Recipients Before and After Revaccination (clinicaltrials.gov) - Mar 6, 2013
P1, N=0, Withdrawn, Sponsor: Intercell Austria AG
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- Ixiaro (IC51) / Valneva
Enrollment change: Immune Response in IXIARO Batch JEV09L37 Recipients Before and After Revaccination (clinicaltrials.gov) - Mar 6, 2013
P1, N=0, Withdrawn, Sponsor: Intercell Austria AG
Not yet recruiting --> Withdrawn N=50 --> 0
- Trial completion, Head-to-Head: Immunogenicity of SA 14-14-2 JE Vaccine (clinicaltrials.gov) - Mar 6, 2013
P4, N=1000, Completed, Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh
N=50 --> 0 Recruiting --> Completed
- ||||| Ixiaro (IC51) / Valneva
Enrollment change, Head-to-Head: Immunogenicity Study of the Japanese Encephalitis Vaccine IC51 (clinicaltrials.gov) - Oct 30, 2012
P3, N=867, Completed, Sponsor: Valneva Austria GmbH
Recruiting --> Completed N=1271 --> 867
- ||||| Ixiaro (IC51) / Valneva
Enrollment change: Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51 (clinicaltrials.gov) - Oct 17, 2012
P3, N=374, Completed, Sponsor: Valneva Austria GmbH
N=1271 --> 867 N=490 --> 374
- ||||||| Typhim Vi (typhoid polysaccharide vaccine) / Sanofi
Trial completion: A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults (clinicaltrials.gov) - Aug 28, 2012
P3, N=552, Completed, Sponsor: Novartis
N=490 --> 374 Active, not recruiting --> Completed
- |||||||||| New P3 trial: Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects (clinicaltrials.gov) - Aug 8, 2012
P3, N=660, Completed, Sponsor: Novartis Vaccines
- New P4 trial: A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2 (clinicaltrials.gov) - Jul 31, 2012
P4, N=20, Recruiting, Sponsor: Indian Institute of Science
- | New P4 trial, Head-to-Head: Immunogenicity of SA 14-14-2 JE Vaccine (clinicaltrials.gov) - Jul 8, 2012
P4, N=1000, Completed, Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh
- New P4 trial, Head-to-Head: Lot-to-lot Consistency Trial of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine (clinicaltrials.gov) - Mar 28, 2012
P4, N=0, Completed, Sponsor: Program for Appropriate Technology in Health
- |||| Ixiaro (IC51) / Valneva
Trial completion: This is a Study to Assess the Safety and Immunogenicity of Ixiaro (clinicaltrials.gov) - Mar 21, 2012
P4, N=200, Completed, Sponsor: Valneva Austria GmbH
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Ixiaro (IC51) / Valneva
New P1 trial: Immune Response in IXIARO Batch JEV09L37 Recipients Before and After Revaccination (clinicaltrials.gov) - Mar 19, 2012
P1, N=0, Withdrawn, Sponsor: Intercell Austria AG
- |||| Trial completion: Safety and Efficacy Study of ChimeriVax (clinicaltrials.gov) - Mar 1, 2012
P2, N=96, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Active, not recruiting --> Completed